Residency Program Director
Katie A. Karkowski, PharmD, BCOP
Clinical Pharmacist Lead, Hematology Medicine
PGY-2 Oncology Residency Program Director
For questions, please email firstname.lastname@example.org.
Residency Program Coordinator
Philip R. Benoit, PharmD, BCOP
Clinical Pharmacist, Hematology/Oncology
PGY-2 Oncology Residency Program Coordinator
For questions, please email email@example.com.
The Norris Cotton Cancer Care Pavilion Lebanon at Dartmouth Hitchcock Medical Center is a National Cancer Institute (NCI) designated comprehensive cancer center. Our pharmacy residency in oncology is a 12-month, full-time, post-graduate year two (PGY-2) training program. The oncology pharmacy residency will expose the resident to challenging and diverse patient populations across a variety of care settings including both inpatient and ambulatory oncology.
The primary goals of the PGY-2 Oncology Pharmacy Residency Program are to:
- Incorporate the resident as part of a multidisciplinary team to improve care of adult and pediatric oncology patients.
- Offer a diverse amount of experiences, allowing the resident to gain exposure in a variety of oncology care settings.
- Prepare the resident to enter the workforce as a clinical specialist, faculty member, or in a leadership role.
- Offer a flexible program, allowing the resident to explore individual interest areas.
- Prepare the resident to take the Board Certified Oncology Pharmacist (BCOP) examination upon graduation from the program.
Required learning experiences
- Ambulatory hematology
- Ambulatory oncology
- Inpatient hematology
- Inpatient oncology
- Investigational pharmacy
- Oral chemotherapy specialty pharmacy
- Palliative care
- Pediatric hematology/oncology
- Practice management
- Transplantation and cellular therapy
Elective learning experiences
- Benign hematology
- Infectious disease
- Repeat of a required rotation
Longitudinal learning experiences
- Medication use evaluation
- Practice management
- Research project
The resident will serve as an active member on both the Hematology/Oncology Drug Specialty P&T Panel and the Dartmouth Cancer Center Medication Safety Committee.
Medication use evaluation
The resident will complete one medication usage evaluation during the first half of the residency year, and present the completed MUE results at the ASHP Midyear/Vizient meeting via a poster presentation.
Longitudinal research project
The resident will complete one longitudinal research project throughout the residency year. This project may be original research or a development/enhancement of pharmacy services. Completed results will be presented as a poster presentation at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference. The resident will also be required to complete a manuscript suitable for publication.
The resident will present two ACPE accredited presentations during the residency year. The topic should surround a controversial oncology topic, new medication, or guideline update.
The resident will participate in both ambulatory and inpatient oncology staffing. The resident will be expected to staff 2 decentralized shifts per month in addition to 1 decentralized weekend every 4 weeks.
If the resident did not complete a teaching certificate program during their PGY-1 pharmacy residency program, there will be an opportunity to participate in a teaching certificate program during the PGY-2 year. We determine the provider of the teaching certificate program on a yearly basis. The resident is not required to participate in this program.
Earned Time: 10 Days plus 6 institutional holidays
- Northeast Hematology/Oncology Pharmacists Symposium (NEHOPS)
- ASHP Midyear Clinical Meeting and Vizient Consortium Pharmacy Network Meeting
- Hematology/Oncology Pharmacy Association (HOPA) Annual Conference
How to apply
Please submit all application materials via PhORCAS.
Application deadline: January 2nd.
You must have a valid pharmacy license to practice in the state of New Hampshire by July 15.
- Letter of intent
- Curriculum vitae
- College transcripts
- Three letters of recommendation
- PhORCAS Residency Program application
- ASHP Residency Matching Program registration
Applications for candidates with a GPA of less than 3.0 on a 4.0 scale, or less than 3.7 on a 5.0 scale will not be accepted. Applications for candidates who have not yet completed a PGY-1 Hematology/Oncology, Investigational Pharmacy, OR Specialty Pharmacy rotation prior to midyear will also not be accepted.